Ottawa – Novo Nordisk spokesperson Kate Hanna in an emailed statement that they are “experiencing a temporary supply disruption with the Ozempic 1 mg (injection) pen due to the combination of overall global supply constraints coupled with increased demand.” The 0.25 mg and 0.5 mg doses of Ozempic injection pens remain available “for patients with Type 2 diabetes across Canada,” Hanna said.
